Essential Thrombocythemia Treatment
Treatment for essential thrombocythemia is determined by thrombosis risk stratification using the revised IPSET-Thrombosis model, with very low/low-risk patients receiving observation or aspirin alone, while high-risk patients (age >60 with JAK2 mutation or prior thrombosis) require cytoreductive therapy with hydroxyurea plus aspirin. 1
Risk Stratification Framework
The revised IPSET-Thrombosis model stratifies patients into four categories based on age, thrombosis history, and JAK2 mutation status 1:
- Very Low Risk: Age ≤60 years, no thrombosis history, JAK2 wild-type
- Low Risk: Age ≤60 years, no thrombosis history, JAK2 mutation present
- Intermediate Risk: Age >60 years, no thrombosis history, JAK2 wild-type
- High Risk: Prior thrombosis at any age OR age >60 years with JAK2 mutation
Treatment Algorithm by Risk Category
Very Low-Risk and Low-Risk Disease
For asymptomatic very low-risk patients, observation without treatment is appropriate. 1
For low-risk patients, aspirin 81-100 mg daily should be considered, though the evidence base is extrapolated from polycythemia vera studies rather than randomized trials in ET 1. Use aspirin with extreme caution in patients with platelet counts >1000 × 10⁹/L due to acquired von Willebrand disease and bleeding risk. 2
Important caveat: Recent retrospective data suggest aspirin may not benefit CALR-mutated ET patients and may increase bleeding risk, though current guidelines do not recommend withholding aspirin based solely on CALR mutation status 1.
Intermediate-Risk Disease
Aspirin 81-100 mg daily is recommended. Cytoreductive therapy is optional and should be initiated only if specific indications develop 1.
High-Risk Disease
High-risk patients require combination therapy: aspirin 81-100 mg daily PLUS cytoreductive therapy. 1
Cytoreductive Therapy Selection
First-Line Options
Hydroxyurea is the first-line cytoreductive agent of choice for most high-risk patients 1. Start at 15-20 mg/kg/day and titrate to maintain platelet count ≤400 × 10⁹/L.
Pegylated interferon-α (interferon alfa-2b, peginterferon alfa-2a, or peginterferon alfa-2b) should be used instead of hydroxyurea for:
- Younger patients (particularly those <40 years old)
- Pregnant patients requiring cytoreduction
- Patients who prefer to avoid hydroxyurea 1
Second-Line Options
Anagrelide is reserved for patients with hydroxyurea resistance or intolerance 1. Hydroxyurea resistance/intolerance is defined by specific criteria including 1:
- Platelet count >600 × 10⁹/L with WBC <2.5 × 10⁹/L at any hydroxyurea dose
- Platelet count >400 × 10⁹/L with hemoglobin <10 g/dL at any hydroxyurea dose
- Leg ulcers or unacceptable mucocutaneous manifestations
- Hydroxyurea-related fever
Busulfan is an alternative second-line option, particularly in elderly patients 3, 4.
Specific Indications for Cytoreductive Therapy
Even in lower-risk patients, cytoreductive therapy should be initiated if any of these develop 1:
- New thrombosis or major bleeding
- Symptomatic or progressive splenomegaly
- Symptomatic thrombocytosis
- Progressive leukocytosis
- Progressive disease-related symptoms (pruritus, night sweats, fatigue)
- Vasomotor/microvascular disturbances not responsive to aspirin (headaches, chest pain, erythromelalgia)
- Extreme thrombocytosis (>1500 × 10⁹/L) 2
Critical pitfall: Perform bone marrow biopsy before initiating cytoreductive therapy to exclude progression to myelofibrosis 1.
Monitoring Strategy
Monitor patients every 3-6 months (or more frequently if clinically indicated) for 1:
- New thrombotic or hemorrhagic events
- Cardiovascular risk factors requiring aggressive management
- Signs of disease progression to myelofibrosis or acute myeloid leukemia
- Response to therapy
Special Considerations
Extreme thrombocytosis (>1000 × 10⁹/L): This is a risk factor for hemorrhage, not thrombosis. Use aspirin with extreme caution and consider withholding until platelet count is reduced with cytoreduction 2.
Cardiovascular risk factors: Aggressively manage hypertension, diabetes, hyperlipidemia, and smoking cessation in all patients, as these significantly increase thrombosis risk beyond the disease itself 2, 5.
Pregnancy: Pegylated interferon is the only cytoreductive agent safe for use during pregnancy 1.
Treatment Goals
The primary objective is preventing thrombohemorrhagic complications 2, 1. Secondary goals include controlling symptoms and potentially reducing progression risk to myelofibrosis (10% at 8.5 years) or acute myeloid leukemia (3% at 10 years) 5, 3.
Cure is not currently possible except through allogeneic stem cell transplantation, which is not indicated for essential thrombocythemia. 2